Pyrazofurin

Pyrazofurin
Clinical data
Trade names	Pyrazofurin
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 3-[(2S,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1H-pyrazole-5-carboxamide;
CAS Number	30868-30-5;
PubChem CID	135413551;
ChemSpider	10570780;
UNII	4B15044GQZ;
KEGG	D05658;
ChEBI	CHEBI:90284;
ChEMBL	ChEMBL2105330;
Chemical and physical data
Formula	C9H13N3O6
Molar mass	259.218 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C([C@@H]1[C@H]([C@H]([C@@H](O1)C2=NNC(=C2O)C(=O)N)O)O)O;
	InChI InChI=1S/C9H13N3O6/c10-9(17)4-6(15)3(11-12-4)8-7(16)5(14)2(1-13)18-8/h2,5,7-8,13-16H,1H2,(H2,10,17)(H,11,12)/t2-,5-,7-,8+/m1/s1; Key:XESARGFCSKSFID-FLLFQEBCSA-N;

Pyrazofurin (pyrazomycin) is a natural product found in Streptomyces candidus, which is a nucleoside analogue related to ribavirin. It has antibiotic, antiviral and anti-cancer properties but was not successful in human clinical trials due to severe side effects. Nevertheless, it continues to be the subject of ongoing research as a potential drug of last resort, or a template for improved synthetic derivatives.